Navigation Links
CPAP treatment effective in patients with milder OSA and daytime sleepiness
Date:7/19/2012

Continuous positive airway pressure (CPAP), well established as an effective treatment for severe obstructive sleep apnea (OSA), is also effective in patients with mild and moderately severe OSA and daytime sleepiness, according to a new study.

"The evidence for the efficacy of CPAP in patients with milder OSA is limited and conflicting," said lead author Terri E. Weaver, PhD, RN, professor and dean of the University of Illinois at Chicago College of Nursing. "Our multi-site, double-blind, randomized trial, the first placebo-controlled study to use sham CPAP in sleepy patients with mild to moderate OSA, shows that CPAP treatment effectively reduces symptoms and improves quality of life in these patients, the largest segment of the OSA population."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

In the study, 239 patients with newly diagnosed milder OSA and self-reported daytime sleepiness (an Epworth Sleepiness Scale (ESS) score > 10) were randomized to eight weeks of active or sham CPAP treatment. After the eight-week intervention, patients in the sham arm were crossed over to eight weeks of active treatment. The primary outcome measure was total score on the Functional Outcomes of Sleep Questionnaire (FOSQ), which measures the impact of daytime sleepiness on activities of daily living.

The adjusted mean change in FOSQ total score after the initial eight-week intervention was 0.89 for actively treated patients and -0.06 for sham-treated patients (p = 0.006). Mean improvement in FOSQ total score from the beginning to the end of the cross-over phase of the study was 1.73 2.50 (p <0.00001). Significant improvements with active treatment were also seen in ESS scores, Physical Component scores on the Short-Form 36 health survey, and Total Mood Disturbance scores on the Profile of Mood States scale.

"The improvements we saw were highly significant and clinically relevant," said Dr. Weaver. "In addition, our study was conducted at both large and smaller clinical practice sites, making our results highly generalizable."

The study had some limitations, including a short mean duration of active daily CPAP treatment (4.0 2.0 hours/day) and a lower mean duration of sham daily CPAP treatment (3.1 2.1 hours/day).

"Given the high prevalence of OSA, our study suggests that there is significant value in treating sleepy patients with mild to moderate disease," concluded Dr. Weaver. "CPAP therapy, the primary treatment for OSA, is highly effective and confers significant health benefits in these patients."


'/>"/>

Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Clinical insight improves treatment with new lung cancer drug
3. Rapid Asthma Treatment in ER May Prevent Admission
4. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
5. Breast cancer patients suffer treatment-related side effects long after completing care
6. Mayo Clinic offers newly approved treatment for acid reflux disease
7. Mobile Stroke Units Might Trim Time to Treatment
8. Breast Cancer Treatment Side Effects May Last for Years
9. Mouse Study Hints at New Path for Diabetes Treatment
10. Symptomatic behaviour in childhood strongly predicts psychiatric treatment as a young adult
11. Exercise improves quality of life during breast cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Orion, MI (PRWEB) , ... March 24, 2017 ... ... insurance assistance, financial planning, and related services to families and business owners across ... initiative aimed at feeding regional families struggling with financial difficulties. , The Oxford/Orion ...
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge dentists, Dr. ... for sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, ... obstructive type, is increasingly being treated at dental offices with newly developed procedures ...
(Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/23/2017)... & Seattle, WA (PRWEB) , ... March 23, 2017 , ... ... health emergency and now estimates that there could be four million Zika-related cases in ... epidemics to date with numbers of US cases reported per year skyrocketing to an ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $3.5 billion ... and forecasts for all the given segments on global as well ...
(Date:3/23/2017)... , March 23, 2017  Transportation Insight, a ... an end-to-end supply chain management firm with expertise serving ... Product Solutions Rick Zaffarano was named a ... the Supply Chain by the only publication exclusively dedicated ... food supply chain. "Rick has brought to ...
(Date:3/23/2017)... SILVER SPRING, Md. , March 23, 2017 /PRNewswire-USNewswire/ ... approval to Bavencio (avelumab) for the treatment of adults ... Merkel cell carcinoma (MCC), including those who have not ... for metastatic MCC, a rare, aggressive form of skin ... the most common cancers, patients with a rare form ...
Breaking Medicine Technology: